Clinical Trials Logo

Filter by:
  • Withdrawn  
  • Page [1]
NCT ID: NCT05387317 Withdrawn - COVID-19 Clinical Trials

Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)

Start date: April 2024
Phase: Phase 3
Study type: Interventional

This is a randomised controlled clinical trial to determine the reactogenicity and immunogenicity of booster doses of SARS-CoV-2 vaccines (Pfizer-BioNTech, AstraZeneca or Moderna) in adults who have previously received either AstraZeneca or Coronavac as their primary doses. Both fractional and standard doses of Pfizer-BioNTech, AstraZeneca and Moderna will be tested.

NCT ID: NCT03106285 Withdrawn - Colic, Infantile Clinical Trials

Effectiveness of Probiotic Supplementation on Crying Time in Infantile Colic

Start date: April 14, 2017
Phase: N/A
Study type: Interventional

This study aims to investigate the effectiveness of Lactobacillus reuteri DSM17938 supplementation on infantile colic in Indonesian infants.

NCT ID: NCT02146664 Withdrawn - Clinical trials for Acute Non-ST Elevation Myocardial Infarction

DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization

Start date: November 2015
Phase: Phase 2/Phase 3
Study type: Interventional

This is a prospective, randomized, double-blind, double-dummy, and controlled study of DLBS1033 in the management of acute non-ST elevation myocardial infarction (NSTEMI) without early coronary revascularization. It is hypothesized that the combination of DLBS1033 with aspirin and clopidogrel will result in greater reduction of infarct size in comparison with that of aspirin and clopidogrel alone.

NCT ID: NCT01972477 Withdrawn - Diabetic Patients Clinical Trials

DLBS1449 in Diabetic Patients With Low HDL

Start date: July 2016
Phase: Phase 2/Phase 3
Study type: Interventional

This is a parallel, 3-arm, randomized, prospective, placebo-controlled, and double-blind clinical study for eight weeks of therapy to investigate the clinical efficacy of DLBS1449 in elevating high density lipoprotein (HDL) cholesterol in diabetic patients. The hypothesis of interest for the study is: the administration of DLBS1449 will elevate HDL-cholesterol level from baseline to the end of study significantly higher than the elevation resulted by placebo. In addition, the administration of DLBS1449 at the dose of 150 mg daily will provide a significantly better response than that of the lower dose (DLBS1449 75 mg daily).